# Robert L. Coleman

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/robert-l-coleman/

## Facts

| Field | Value |
| --- | --- |
| Citations | 53,839 |
| Field | Ovarian cancer diagnosis and treatment |
| h-index | 105 |
| i10-index | 476 |
| Last Known Institution | Texas Oncology |
| OpenAlex ID | https://openalex.org/A5009234043 |
| ORCID iD | 0000-0001-9343-8754 |
| Works | 1,362 |

## Researcher papers

Showing 12 of 23.

- [Minimally Invasive versus Abdominal Radical Hysterectomy for Cervical Cancer](https://scholariq.org/papers/minimally-invasive-versus-abdominal-radical-hysterectomy-for-cervical-cancer/)
- [Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial](https://scholariq.org/papers/rucaparib-maintenance-treatment-for-recurrent-ovarian-carcinoma-after-response/)
- [2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial](https://scholariq.org/papers/2-year-follow-up-of-trastuzumab-after-adjuvant-chemotherapy-in-her2-positive/)
- [Chronic stress promotes tumor growth and angiogenesis in a mouse model of ovarian carcinoma](https://scholariq.org/papers/chronic-stress-promotes-tumor-growth-and-angiogenesis-in-a-mouse-model-of/)
- [Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial](https://scholariq.org/papers/rucaparib-in-relapsed-platinum-sensitive-high-grade-ovarian-carcinoma-ariel2/)
- [Bevacizumab (Avastin®) in cancer treatment: A review of 15 years of clinical experience and future outlook](https://scholariq.org/papers/bevacizumab-avastin-in-cancer-treatment-a-review-of-15-years-of-clinical/)
- [Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer: meta-analysis of individual patient data from ten randomised trials](https://scholariq.org/papers/long-term-outcomes-for-neoadjuvant-versus-adjuvant-chemotherapy-in-early-breast/)
- [Veliparib with First-Line Chemotherapy and as Maintenance Therapy in Ovarian Cancer](https://scholariq.org/papers/veliparib-with-first-line-chemotherapy-and-as-maintenance-therapy-in-ovarian/)
- [Dostarlimab for Primary Advanced or Recurrent Endometrial Cancer](https://scholariq.org/papers/dostarlimab-for-primary-advanced-or-recurrent-endometrial-cancer/)
- [RNA interference in the clinic: challenges and future directions](https://scholariq.org/papers/rna-interference-in-the-clinic-challenges-and-future-directions/)
- [Bevacizumab and paclitaxel–carboplatin chemotherapy and secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer (NRG Oncology/Gynecologic Oncology Group study GOG-0213): a multicentre, open-label, randomised, phase 3 trial](https://scholariq.org/papers/bevacizumab-and-paclitaxel-carboplatin-chemotherapy-and-secondary-cytoreduction/)
- [Final Overall Survival of a Randomized Trial of Bevacizumab for Primary Treatment of Ovarian Cancer](https://scholariq.org/papers/final-overall-survival-of-a-randomized-trial-of-bevacizumab-for-primary/)

## Researcher topics

- [Ovarian cancer diagnosis and treatment](https://scholariq.org/topics/ovarian-cancer-diagnosis-and-treatment/)
- [PARP inhibition in cancer therapy](https://scholariq.org/topics/parp-inhibition-in-cancer-therapy/)
- [Endometrial and Cervical Cancer Treatments](https://scholariq.org/topics/endometrial-and-cervical-cancer-treatments/)
- [Angiogenesis and VEGF in Cancer](https://scholariq.org/topics/angiogenesis-and-vegf-in-cancer/)
- [Intraperitoneal and Appendiceal Malignancies](https://scholariq.org/topics/intraperitoneal-and-appendiceal-malignancies/)

## Researcher university

- [Texas Oncology](https://scholariq.org/institutions/texas-oncology/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.